A metabolically stable second-generation SERCA2a SUMOylation enhancer improves cardiac function in heart failure
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY218 · pp.55 · 2026
- 피인용
- Web of Science 0Scopus 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 4.7
- ISSN
- 0022-2828
저자
- 이아영제1저자Pusan Natl Univ, Sch Korean Med, Yangsan, South Korea
- Oh, Jae GyunIcahn Sch Med Mt Sinai, Cardiovasc Res Inst, New York, NY USA
- Mitsuyama, ShinichiMatsubara Tokushukai Hosp, Dept Cardiovasc Surg, Osaka, Japan
- Wang, HuiIcahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY USA
- 권하영Pusan Natl Univ, Sch Korean Med, Yangsan, South Korea
- Jeong, DongtakHanyang Univ, Coll Sci & Convergence Technol, Dept Mol & Life Sci, ERICA, Ansan, South Korea
- Ishikawa, KiyotakeIcahn Sch Med Mt Sinai, Cardiovasc Res Inst, New York, NY USA
- DeVita, Robert J.Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY USA
- Hajjar, Roger J.Massachusetts Gen Brigham, Gene & Cell Therapy Inst, Boston, MA USA
- 고창원교신저자Pusan Natl Univ, Sch Korean Med, Yangsan, South Korea
초록
Aims Impaired SUMOylation of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA2a) is a key contributor to defective calcium cycling and contractile dysfunction in heart failure (HF). Although N106 was previously identified as a first-in-class small-molecule enhancer of SERCA2a SUMOylation, its poor metabolic stability and short half-life limited translational development. This study aimed to develop SC023, a second-generation analog with improved pharmacokinetic (PK) properties and therapeutic efficacy. Methods and results Through structure-activity relationship (SAR) screening of 100 analogs, SC023 was identified as the lead candidate. SC023 demonstrated 1.5-fold higher in vitro SUMO E1 hydrolysis activity than N106 and dose-dependently enhanced SERCA2a SUMOylation, contractility, and calcium handling in isolated adult cardiomyocytes. SC023 exhibited significantly improved metabolic stability, with a 2.7-fold longer half-life in human hepatocytes and 14.4-fold longer oral half-life in mice compared with N106. In a murine transverse aortic constriction model, chronic oral administration of SC023 for one month significantly restored left ventricular systolic function and attenuated adverse remodeling. Mechanistically, SC023 targets the SUMO E1 enzyme to trigger intrinsic SERCA2a SUMOylation without altering SUMO-related regulatory enzymes. Importantly, safety profiling confirmed that SC023 exhibited reduced off-target activity, specifically lacking the adenosine A2A and serotonin 5-HT2B receptor inhibition observed with N106. Conclusions SC023 is a potent, metabolically stable second-generation SERCA2a SUMOylation enhancer that overcomes the PK and safety limitations of N106. Sustained pharmacological enhancement of SERCA2a SUMOylation by SC023 represents a promising therapeutic strategy for restoring calcium homeostasis and cardiac function in HF.
키워드
DMPKHeart failurePharmacokineticsSmall molecule therapySUMOylation
식별자
- Scopus EID
- 2-s2.0-105045388168
- WoS UID
- 001833794200001



로그인
연구물 목록으로